Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer, with an increasing global incidence. While most cases are successfully treated with surgical excision, a subset can metastasize, leading to significant morbidity and mortality. Current staging systems based on clinical and histopathological features have shown limitations in accurately predicting metastatic risk. This review examines the role of gene expression profiling (GEP), particularly the 40-gene expression profile (40-GEP) test, in improving risk stratification and management of cSCC. We assess the prognostic value of the 40-GEP test, its integration with current staging systems, and its impact on clinical decision-making. Recent studies suggest that incorporating GEP results with traditional staging methods can enhance the identification of high-risk patients, potentially leading to more personalized treatment strategies. The review also explores the challenges of implementing GEP in routine clinical practice, including cost-effectiveness considerations and the need for standardization. Finally, we discuss the implications for future cSCC management and highlight areas for further research. As molecular profiling techniques continue to evolve, GEP represents a promising approach to optimizing care for cSCC patients, aligning with the growing emphasis on personalized medicine in oncology.
皮肤鳞状细胞癌（cSCC）是第二常见的皮肤癌类型，全球发病率持续上升。虽然大多数病例可通过手术切除成功治愈，但部分病例会发生转移，导致显著的发病率和死亡率。目前基于临床和组织病理学特征的分期系统在准确预测转移风险方面存在局限性。本综述探讨了基因表达谱（GEP）分析，特别是40基因表达谱（40-GEP）检测在改善cSCC风险分层和管理中的作用。我们评估了40-GEP检测的预后价值、其与现有分期系统的整合及其对临床决策的影响。近期研究表明，将GEP结果与传统分期方法结合可提高高危患者的识别率，可能推动更个性化的治疗策略。本文还探讨了在常规临床实践中应用GEP所面临的挑战，包括成本效益考量及标准化需求。最后，我们讨论了其对未来cSCC管理的意义，并指出需要进一步研究的领域。随着分子谱分析技术的不断发展，GEP代表了优化cSCC患者诊疗的可行路径，符合肿瘤学领域日益重视的个体化医疗趋势。
The Role of Gene Expression Profiling in the Management of Cutaneous Squamous Cell Cancer: A Review
肿瘤(癌症)患者之家